AngioDynamics to Report Fiscal 2014 Second Quarter Financial Results
ALBANY, N.Y., Dec. 12, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a
leading provider of innovative, minimally invasive medical devices for
vascular access, surgery, peripheral vascular disease and oncology, today
announced it will report its fiscal 2014 second quarter financial results for
the period ended November 30, 2013, on Thursday, January 9, 2014, after the
close of the U.S. financial markets.
Management will host a conference call beginning at 4:30 p.m. Eastern Time on
January 9, 2014, to discuss the results and to answer questions.
To participate in the live call by telephone, please call 1-877-941-8609.
A live webcast and subsequent archived replay of the conference call may be
accessed via the investor relations section of the Company's website under
"Events & Presentations" at http://investors.angiodynamics.com/events.cfm. To
listen to the live webcast, please go to the website 15 minutes prior to its
start to register, download and install the necessary audio software.
AngioDynamics Inc. is a leading provider of innovative, minimally invasive
medical devices used by professional healthcare providers for vascular access,
surgery, peripheral vascular disease and oncology. AngioDynamics' diverse
product lines include market-leading ablation systems, fluid management
systems, vascular access products, angiographic products and accessories,
angioplasty products, drainage products, thrombolytic products and venous
products. More information is available at www.AngioDynamics.com.
AngioDynamics and the AngioDynamics logo are trademarks and/or registered
trademarks of AngioDynamics Inc., an affiliate or a subsidiary.
This release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements regarding
AngioDynamics' expected future financial position, results of operations, cash
flows, business strategy, budgets, projected costs, capital expenditures,
products, competitive positions, growth opportunities, plans and objectives of
management for future operations, as well as statements that include the words
such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes,"
"seeks," "estimates," "optimistic," or variations of such words and similar
expressions, are forward-looking statements. These forward looking statements
are not guarantees of future performance and are subject to risks and
uncertainties. Investors are cautioned that actual events or results may
differ from AngioDynamics' expectations. Factors that may affect the actual
results achieved by AngioDynamics include, without limitation, the ability of
AngioDynamics to develop its existing and new products, technological advances
and patents attained by competitors, future actions by the FDA or other
regulatory agencies, domestic and foreign health care reforms and government
regulations, results of pending or future clinical trials, overall economic
conditions, the results of on-going litigation, the effects of economic,
credit and capital market conditions, general market conditions, market
acceptance, foreign currency exchange rate fluctuations, the effects on
pricing from group purchasing organizations and competition, the ability of
AngioDynamics to integrate purchased businesses, including Navilyst Medical
and its products, R&D capabilities, infrastructure and employees as well as
the risk factors listed from time to time in AngioDynamics' SEC filings,
including but not limited to its Annual Report on Form 10-K for the year ended
May 31, 2013. AngioDynamics does not assume any obligation to publicly update
or revise any forward-looking statements for any reason.
CONTACT: Company Contact:
Mark Frost, CFO
(800) 772-6446 x1981
Investor Relations Contacts:
EVC Group, Inc.
Michael Polyviou/Robert Jones
(212) 850-6020; (646) 201-5447
EVC Group, Inc.
Press spacebar to pause and continue. Press esc to stop.